NG25 Enhances Anti-Tumor Immunity in KRAS-Mutant Colorectal Cancer.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• KRAS-mutant colorectal cancer has a poor prognosis due to an immunosuppressive tumor microenvironment and limited targeted therapies.
• Transforming growth factor-β-activated kinase 1 (TAK1) is a key regulator of NF-κB and MAPK pathways, promoting tumor progression when aberrantly activated.

Purpose of the Study:

• To investigate the anti-tumor and immunomodulatory effects of the TAK1 inhibitor NG25 in KRAS-mutant colorectal cancer.
• To assess NG25's impact on T cell differentiation, PD-L1 expression, and tumor immune microenvironment remodeling.

Main Methods:

• In vitro tumor cell-lymphocyte co-culture system.
• Orthotopic colorectal cancer models in immunodeficient and immunocompetent mice.
• Evaluation of spleen and thymus indices, lymphocyte proliferation, and T cell subset proportions.
• Mechanistic studies on TAK1/NF-κB signaling and PD-L1 expression.

Main Results:

• NG25 suppressed tumor progression in immunocompetent mice, increasing spleen/thymus indices and promoting T and B lymphocyte proliferation.
• NG25 treatment promoted CD8+ T cell infiltration and increased CD3+CD8+ T cell subsets within the tumor microenvironment.
• NG25 downregulated PD-L1 expression on KRAS-mutant tumor cells and T cells by inhibiting the TAK1/NF-κB axis, an effect not observed in KRAS wild-type cells.

Conclusions:

• NG25 targets TAK1 to block the NF-κB pathway, remodeling the immunosuppressive microenvironment in KRAS-mutated colorectal cancer.
• NG25 reduces PD-1 expression and enhances anti-tumor CD8+ T cell activity.
• This study provides a rationale for TAK1-targeted therapy and a novel immunotherapy strategy for KRAS-mutated colorectal cancer.